These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20061004)

  • 21. [The role of bisphosphonates of adjuvant therapy in breast cancer].
    Gálvez-Muñoz E; Rodríguez-Lescure Á
    Med Clin (Barc); 2010 Jun; 135(2):70-4. PubMed ID: 20022069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
    Lancet; 2015 Oct; 386(10001):1353-1361. PubMed ID: 26211824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials.
    Hald JD; Evangelou E; Langdahl BL; Ralston SH
    J Bone Miner Res; 2015 May; 30(5):929-33. PubMed ID: 25407702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials.
    Chen L; Wang G; Zheng F; Zhao H; Li H
    Osteoporos Int; 2015 Sep; 26(9):2355-63. PubMed ID: 25944731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.
    Yan T; Yin W; Zhou Q; Zhou L; Jiang Y; Du Y; Shao Z; Lu J
    Eur J Cancer; 2012 Jan; 48(2):187-95. PubMed ID: 22100904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphosphonates for Patients Diagnosed With Multiple Myeloma.
    Mhaskar R; Djulbegovic B
    JAMA; 2018 Oct; 320(14):1483-1484. PubMed ID: 30326511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
    Gnant M; Dubsky P; Fitzal F; Blaha P; Schoppmann S; Steger G; Marth C; Samonigg H; Hüttner K; Fohler H; Ruecklinger E; Jakesz R; Greil R;
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S18-27. PubMed ID: 19561003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
    Ben-Aharon I; Vidal L; Rizel S; Yerushalmi R; Shpilberg O; Sulkes A; Stemmer SM
    PLoS One; 2013; 8(8):e70044. PubMed ID: 23990894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can Bisphosphonates Prevent Recurrent Fragility Fractures? A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Lee SY; Jung SH; Lee SU; Ha YC; Lim JY
    J Am Med Dir Assoc; 2018 May; 19(5):384-390.e1. PubMed ID: 29704927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of osteoporosis after breast cancer.
    Reid DM
    Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis.
    Migliore A; Broccoli S; Massafra U; Cassol M; Frediani B
    Eur Rev Med Pharmacol Sci; 2013 Mar; 17(5):658-67. PubMed ID: 23543450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
    Brufsky AM; Harker WG; Beck JT; Bosserman L; Vogel C; Seidler C; Jin L; Warsi G; Argonza-Aviles E; Hohneker J; Ericson SG; Perez EA
    Cancer; 2012 Mar; 118(5):1192-201. PubMed ID: 21987386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical benefits of bone targeted agents in early breast cancer.
    Coleman R
    Breast; 2019 Nov; 48 Suppl 1():S92-S96. PubMed ID: 31839171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
    Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
    Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing the risk of bone loss associated with breast cancer treatment.
    Hadji P
    Breast; 2007 Dec; 16 Suppl 3():S10-5. PubMed ID: 18023583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonates in the adjuvant treatment of breast cancer.
    Winter MC; Coleman RE
    Clin Oncol (R Coll Radiol); 2013 Feb; 25(2):135-45. PubMed ID: 23207072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
    Aft R
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):194-205. PubMed ID: 21475125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.